Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 vaccine booster in patients on maintenance dialysis

Karakizlis, Hristos; Agarwal, Vipul; Aly, Mostafa; Strecker, Kevin; Csala, Benjamin; Esso, Isla; Chen, Jiangping; Nahrgang, Christian; Wolter, Martin; Slanina, Heiko; Schüttler, Christian G.; Jessen, Sönke; Ronco, Claudio; Seeger, Werner; Weimer, Rolf; Sester, Martina; Husain‐Syed, Faeq

doi:10.1007/s40620-022-01371-4

Cited by 5 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, after the booster dose, all four showed a strong cellular and humoral immunity, which is evidence that the vaccine booster was very effective in dialysis patients. The same conclusion has been obtained from other series of patients by increasing antibodies such as cell-mediated immunity [ 23 , 24 ]. In our study and in others [24] we observed that cellular immunity is maintained over time and not decreases rapidly as occurs with antibodies.…”

Section: Discussionsupporting

confidence: 84%

“…The same conclusion has been obtained from other series of patients by increasing antibodies such as cell-mediated immunity [ 23 , 24 ]. In our study and in others [24] we observed that cellular immunity is maintained over time and not decreases rapidly as occurs with antibodies. In patients under dialysis, the increased immunity caused by the booster dose even protects against non-vaccine variants such as Omicron [25] .…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients

Urra

Castro

Jiménez

et al. 2023

Clinical Immunology Communications

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 84%

Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients

Urra

Castro

Jiménez

et al. 2023

Clinical Immunology Communications

View full text Add to dashboard Cite

“…Moreover, those responses were found out to be transient [ 18 ]. On the other hand, recent evidence also suggests that vaccines for SARS-CoV-2 could induce robust cellular and humoral responses in patients undergoing MHD [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. We showed that both BNT162b2 and CoronaVac elicited good humoral responses in a naïve MHD population, yet the antibody levels started to wane over time.…”

Section: Discussionmentioning

confidence: 99%

Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study

Mirioglu

Kazancıoğlu

Cebeci

et al. 2023

Nephron

View full text Add to dashboard Cite

Introduction: Data regarding inactivated vaccines for SARS-CoV-2 in patients undergoing maintenance hemodialysis (MHD) are limited. We aimed to investigate humoral responses induced by CoronaVac compared to BNT162b2 in this population. Methods: In this multicenter prospective cohort study, adult patients undergoing MHD who lacked a history of COVID-19 and decided to get vaccinated with BNT162b2 or CoronaVac were enrolled. Participants provided serum samples before, 1 and 3 months after 2 doses. Anti-SARS-CoV-2 IgG antibodies against receptor-binding domain of the virus were measured, and levels ≥50 AU/mL were considered as positive. Breakthrough infections and adverse events were recorded. Results: Ninety-two patients were included, 68 (73.9%) of whom were seronegative at baseline. BNT162b2 and CoronaVac were administered in 38 (55.9%) and 30 (44.1%) patients. At 1 month, seropositivity was 93.1% in BNT162b2 and 88% in CoronaVac groups (p = 0.519). Quantitative antibody levels were significantly higher in BNT162b2 (p < 0.001). At 3 months, both seropositivity (96.4% and 78.3%, p = 0.045) and antibody levels (p = 0.001) remained higher in BNT162b2 compared to CoronaVac. Five patients (7.4%) experienced breakthrough COVID-19. Adverse events were more frequent with BNT162b2, although all of them were mild. Multiple linear regression model showed that only vaccine choice (BNT162b2) was related to the humoral response (β = 0.272, p = 0.038). Seropositive patients at baseline (n = 24) had higher antibody levels at any time point. Conclusions: BNT162b2 and CoronaVac induced humoral responses in naïve patients undergoing MHD, which were more robust and durable for 3 months after BNT162b2. Both vaccines created high antibody levels in patients who were seropositive at baseline.

show abstract

“…Similarly, a previous study by Karakizlis et al also demonstrated that haemodialysis patients with COVID-19 past infections sustained higher anti-SARS-CoV-2-spike levels compared to infection-naïve patients after the primary vaccination. However, both groups reached the upper detection limit of 40,000 AU/mL after the booster dose administration [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

et al. 2023

View full text Add to dashboard Cite

Background A significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose to increase the antibody titres after vaccination. Consequently, it is crucial to analyse the long-term humoral immune responses after COVID-19 primary vaccination and assess the immunogenicity and safety of booster doses in haemodialysis (HD) patients. Methods Patients on maintenance haemodialysis who received the primary vaccine of CoronaVac (Sinovac) vaccine were administered with BNT162b2 (Pfizer-BioNTech) as the booster dose. The immunogenicity was assessed before (V1), one month (V2) and eight months (V3) after the primary vaccination, as well as one month after the booster dose (V4). Patients were followed up one month after the booster dose to assess the adverse events (AEs). Results The geometric mean titre (GMT) of anti-SARS-CoV-2 S-RBD IgG antibody at 8 months after the primary vaccination increased significantly to 5,296.63 (95%CI: 2,930.89–9,571.94) U/mL (p = < 0.0001) compared to before the primary vaccination. The GMT also increased significantly to 19,142.56 (95% CI: 13,489.63–27,227.01) U/mL (p < 0.0001) 1 month after the booster vaccine. Meanwhile, the median inhibition rate of neutralizing antibodies (NAbs) at 8 months after the primary vaccine and 1 month after the booster dose were not significantly different (p > 0.9999). The most common AEs after the booster dose included mild pain at the injection site (55.26%), mild fatigue (10.53%), and swelling at the injection site (10.53%). No serious AEs were reported. Conclusions The majority of ESKD patients on haemodialysis mounted a good antibody response to the BNT162b2 booster vaccination with tolerable adverse events.

show abstract

Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 vaccine booster in patients on maintenance dialysis

Cited by 5 publications

References 5 publications

Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients

Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients

Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study

Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

Contact Info

Product

Resources

About